Beijing, Beijing, China Source Capital is the famous VC, which was founded in 2002. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Atlanta.
We can highlight the next thriving fund investment areas, such as Industrial, Manufacturing. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular portfolio startups of the fund, we may highlight Yingsheng Biology, JuLive.com.
This Source Capital works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year.
The standard case for the fund is to invest in rounds with 1-2 partakers. The meaningful sponsors for the fund in investment in the same round are Yahui Precision Medicine Fund. In the next rounds fund is usually obtained by Xiamen C&D Corporation, Vertex Ventures China, Vertex Ventures.
| Fund Name | Location |
| Declaration Capital | New York, New York, United States |
| Gatebridge Investments | Dallas, Texas, United States |
| HealthCor Partners | Charleston, South Carolina, United States |
| Insignia Ventures Partners | Central Region, Singapore, Singapore |
| JIERLING Business Consulting | - |
| LEAD | Linköping, Ostergotlands Lan, Sweden |
| Multiple Myeloma Research Foundation | Connecticut, Norwalk, United States |
| Pamoja Capital Group | Luxembourg, Luxembourg |
| Seligman Private Equity Select | England, London, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Moody | $39M | 25 Feb 2021 | Shanghai, Shanghai, China | ||
Moody | $19M | 28 Jan 2021 | Shanghai, Shanghai, China | ||
Yingsheng Biology | 21 Jul 2018 | Lixia District, Shandong | |||
Frasergen | $7M | 12 Nov 2017 | Jiang'an District, Hubei, China | ||
Geneis | $1M | 07 Feb 2017 | Dongcheng District, Beijing, China | ||
FTS | $3M | 16 Mar 2016 | Haidian District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Moody | $39M | 25 Feb 2021 | Shanghai, Shanghai, China | ||
Moody | $19M | 28 Jan 2021 | Shanghai, Shanghai, China | ||
Yingsheng Biology | 21 Jul 2018 | Lixia District, Shandong | |||
Frasergen | $7M | 12 Nov 2017 | Jiang'an District, Hubei, China | ||
Geneis | $1M | 07 Feb 2017 | Dongcheng District, Beijing, China | ||
FTS | $3M | 16 Mar 2016 | Haidian District, Beijing, China |
